Gen-Probe expands Dx offering with Prodesse buy
This article was originally published in Clinica
Executive Summary
In a bid to diversify its range of molecular tests for infectious diseases, Gen-Probe is to purchase Prodesse for $60m in cash. The deal, which is expected to close in the next month, could reach $85m if Prodesse achieves certain financial and regulatory milestones in 2010 and 2011.